Ibrutinib was selected as it is the main BCR-associated kinase inhibitor used for the treatment of CLL and was used at 100 nM as this concentration fully blocks BTK activity in cells and is clinically achievable [45]. This evidence concerns the gene BTK and B-cell chronic lymphocytic leukemia.